Endo Pharmaceuticals Recognizes 10 Years as a Public Company by Ringing the NASDAQ Opening Bell
CHADDS FORD, Pa., July 19 /PRNewswire-FirstCall/ — Endo Pharmaceuticals (Nasdaq: ENDP) CEO Dave Holveck, along with company executives, will mark Endo’s 10th anniversary as a publicly traded company by ringing the opening bell at the NASDAQ Marketsite on Monday, July 19, in Times Square in New York.
Endo and its employees will be recognizing this milestone at an important juncture in the company’s history. In recent years, Endo Pharmaceuticals has elevated itself from a marketer of products primarily in the pain space into a full-service healthcare solutions provider – developing drugs, treatments, devices, diagnostics and services in pain, urology, oncology and endocrinology.
“This has been an amazing and transformative decade for Endo Pharmaceuticals. Our company is responding to a new era in healthcare by offering more products, filling gaps in demand, delivering innovative solutions and providing more effective care to patients,” said Dave Holveck, president and CEO of Endo. “We have, with the help of our employees and partners, responded to a dramatically changing healthcare environment and built our company to be a uniquely diversified provider of multiple medical solutions.
“We have taken this company through a tremendous amount of change, and today we are well positioned to be an even better partner to physicians, payment providers and patients by offering multiple products and platforms and by identifying the assets the company needs to succeed,” Holveck said. “These are exciting times at Endo, and we look forward to the next 10 years.”
The Endo NASDAQ Marketsite opening bell ceremony will be Monday, July 19, beginning at 9 a.m. EDT. Live webcast of the event will be available at www.nasdaq.com.
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, bladder cancer, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; Percocet(R) and Percodan(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren(R) Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; VANTAS(R) for the palliative treatment of advanced prostate cancer; SUPPRELIN(R) LA for the treatment of early onset puberty in children; and VALSTAR(TM) for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable medical risks. The company markets its branded pharmaceutical products to physicians in pain management, urology, endocrinology, oncology, neurology, surgery and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.
SOURCE Endo Pharmaceuticals